BTK and myeloid sarcoma: Although there are no clinical studies were performed using BTK inhibitors such as ibrutinib to treat ICH, BTK inhibitors have been used in several clinical trials to treat autoimmune neurological diseases such as MS (NCT04410978, NCT04410991, NCT04411641) and NMOSD (NCT05356858).